MSMayara Coelho Sa

Mayara Coelho Sa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mayara Coelho Sa has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Zinc Bismuthate-Based Nanocomposites: Promising Antimicrobial Properties for Biomedical Applications

    by Felipe R. Silva, Edson T. de Jesus, Mayara C. Sá, Margaret Dawson, Thaynara R. Santos, Alan S. de Menezes, Clenilton C. dos Santos, Ulisses M. Nascimento, Érima J. M. Castro, Rita de Cássia M. de Miranda, et al.

    The growing threat of antimicrobial resistance has intensified the search for new antimicrobial materials. In this work, zinc bismuthate-based nanocomposites (ZB1 and ZB4) were synthesized by a hydrothermal method and characterized using X-ray diffraction, Raman spectroscopy, zeta potential and high-resolution transmission electron microscopy. Structural analyses suggested the coexistence of a zinc oxide secondary phase and oxygen vacancies, which may influence the physicochemical and biological behavior of the materials. The antimicrobial activity was evaluated against Staphylococcus aureus, Corynebacterium diphtheriae, Klebsiella pneumoniae, Cryptococcus neoformans, and Candida albicans by disk diffusion. For C. diphtheriae and C. neoformans, additional minimum inhibitory concentration and minimum fungicidal concentration assays were performed. Both nanocomposites inhibited S. aureus, C. diphtheriae, and C. neoformans, while no inhibition was observed for C. albicans and K. pneumoniae. ZB4 exhibited superior antimicrobial activity, with growth inhibition observed up to 500 µg mL-1, whereas ZB1 was effective only at higher concentrations. Toxicity tests using Tenebrio molitor larvae revealed survival rates of approximately 70% for ZB1 and 60% for ZB4 after 10 days, with no statistically significant difference compared to the control. Overall, ZB4 presented promising antimicrobial activity with moderate toxicity, indicating its potential for biomedical applications.

  • Open Access

    Zinc Bismuthate-Based Nanocomposites: Promising Antimicro-Bial Properties for Biomedical Applications

    by Felipe Rodrigues Silva, Edson Tobias De Jesus, Mayara Coelho Sa, Margaret Dawson, Thaynara Ramalho Santos, Alan S. de Menezes, Clenilton C. dos Santos, Ulisses Magalhaes Nascimento, Erima Joyssielly Mendonça Castro, Rita de Cassia Mendonça de Miranda, et al.

    Background/Objectives: The growing threat of antimicrobial resistance (AMR) has inten-sified the search for innovative antimicrobial materials. Herein, we synthesized and characterized zinc bismuthate-based nanocomposites (ZB1 and ZB4) and investigated their antimicrobial efficacy against two Gram-positive bacteria (Staphylococcus aureus and Corynebacterium diphtheriae), one Gram-negative bacterium (Klebsiella pneumoniae), and two fungal pathogens (Cryptococcus neoformans and Candida albicans). Toxicity was further as-sessed using Tenebrio molitor larvae as an alternative model. Methods: Nanocomposites were prepared via a hydrothermal process and characterized using X-ray diffraction (XRD), Raman spectroscopy, Zeta potential, and high-resolution transmission electron microscopy (HR-TEM). Antimicrobial activity was evaluated through disk diffusion as-says coupled with minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) assessments. Results: ZB1 and ZB4 inhibited S. aureus (10.7 ± 1.2 mm and 11.3 ± 1.2 mm), C. diphtheriae (10.7 ± 1.1 mm and 11.3 ± 1.1 mm), and C. neoformans (10.7 ± 1.1 mm and 11.7 ± 2.9 mm), while no inhibition was observed for C. albicans and K. pneumoniae. From MIC and MFC evaluations, ZB1 was effective up to 1000 μg/mL, and ZB4 up to 500 μg/mL. Toxicity assays revealed survival rates of 70% for ZB1 and 60% for ZB4, with no statistically significant differences compared to the control (p = 0.156). Notably, ZB4 is a promising candidate due to its enhanced antimicrobial performance and moderate toxicity. Conclusions: Our findings highlight ZB1 and ZB4 nanocomposites as promising antimicrobial agents, offering new avenues in nanotechnology-driven healthcare solutions aimed at tackling antimicrobial resistance.


  • Open Access

    Design of Liquid Formulation Based on F127-Loaded Natural Dimeric Flavonoids as a New Perspective Treatment for Leishmaniasis

    by Camila Silva da Costa, Estela Mesquita Marques, Jessyane Rodrigues Do Nascimento, Victor Antônio Silva Lima, Ralph Santos-Oliveira, Aline Santana Figueredo, Caroline Martins de Jesus, Glécilla Colombelli de Souza Nunes, Clenilma Marques Brandão, Edson Tobias de Jesus, et al.

    Infectious and Parasitic Diseases (IPD) remain a challenge for medicine due to several interconnected reasons, such as antimicrobial resistance (AMR). American tegumentary leishmaniasis (ATL) is an overlooked IPD causing persistent skin ulcers that are challenging to heal, resulting in disfiguring scars. Moreover, it has the potential to extend from the skin to the mucous membranes of the nose, mouth, and throat in both humans and various animals. Given the limited effectiveness and AMR of current drugs, the exploration of new substances has emerged as a promising alternative for ATL treatment. Arrabidaea brachypoda (DC). Bureau is a native Brazilian plant rich in dimeric flavonoids, including Brachydin (BRA), which displays antimicrobial activity, but still little has been explored regarding the development of therapeutic formulations. In this work, we present the design of a low-cost liquid formulation based on the use of Pluronic F127 for encapsulation of high BRA concentration (LF-B500). The characterization techniques revealed that BRA-loaded F127 micelles are well-stabilized in an unusual worm-like form. The in vitro cytotoxicity assay demonstrated that LF-B500 was non-toxic to macrophages but efficient in the inactivation of forms of Leishmania amazonensis promastigotes with IC50 of 16.06 µg/mL. The results demonstrated that LF-B500 opened a new perspective on the use of liquid formulation-based natural products for ATL treatment.